Zakile A Mfumbilwa
Zakile A Mfumbilwa is an expert in Oncology at Sokoine University of Agriculture (Tanzania). Zakile A Mfumbilwa has authored 8 publications, the most recent in 2025. SLR score: 28 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties:
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2021 - 2026
Number : 8
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| African Swine Fever Perception, Risk Factors, and Socioeconomic Disparities Among Smallholder Domestic Pig Farmers in Serengeti, Tanzania. PMID 40909123 — disease outbreaks, polymerase chain reaction, farms, perception, veterinary medicine, viruses, risk factors, african swine fever, classical swine fever | Transbound Emerg Dis | 2025 | 0 |
| Cost-Effectiveness of Pembrolizumab Monotherapy for High Programmed Death Ligand 1 Advanced or Metastatic Non-small Cell Lung Cancer Depends on Long-Term Survivors. PMID 40632461 — cells, b7-h1 antigen, lung, pharmaceutical preparations, neoplasms, carcinoma, non-small-cell lung, drug therapy, lung neoplasms, small cell lung carcinoma, quality-adjusted life years, therapeutics, ligands, chemotherapy | Clin Drug Investig | 2025 | 0 |
| Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy. PMID 38194023 — research design, health care costs, biomarkers, immunotherapy, cells, therapeutics, lung neoplasms, mutation, small cell lung carcinoma, quality-adjusted life years, whole genome sequencing, chemotherapy | Pharmacoeconomics | 2024 | 4 |
| Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands. PMID 36759641 — lung, neoplasms, carcinoma, non-small-cell lung, drug therapy, immunotherapy, lung neoplasms, diagnosis, natural science disciplines, therapeutics, chemotherapy | Sci Rep | 2023 | 2 |
| Cost-Effectiveness of Parallel Versus Sequential Testing of Genetic Aberrations for Stage IV Non-Small-Cell Lung Cancer in the Netherlands. PMID 35834758 — research design, carcinoma, non-small-cell lung, cells, therapeutics, lung neoplasms, precision medicine, small cell lung carcinoma, genes, quality-adjusted life years, high-throughput nucleotide sequencing | JCO Precis Oncol | 2022 | 32 |
LeadR Networks
Main global connection map